Abstract: Disclosed are methods, systems and non-transitory computer readable memory for free-space optical (FSO) communications. For instance, a communications network may include FSO optical transceiver terminals located at remote electrically unpowered locations within the communications network. A remote unpowered FSO terminal located at a far-end location receives necessary optical power from a powered base station location (near-end) required for all optical amplification functions for NRZ or RZ format signals within the spectral range of 900 nm to 1480 nm as well as an Ultra Short Pulsed Laser (USPL) centered at 1560 nm at the far-end location. A transmitting node transmits an optical signal identified as a pump signal to a remote location over a free space medium, such as the atmosphere, where the remote location does not have available electrical power for operation of electro-optic components required for transmission and retransmission functions.

Abstract: A method of operating a device, which includes providing a user interface with a display artifact; in response to an indication a user selected to copy the display artifact, storing multiple levels of detail of the display artifact; allowing the user to paste a selected level of detail by steps of: in response to an indication a user selected an input field and a paste command, displaying a plurality of paste options for pasting the display artifact into the input field, wherein the plurality of paste options each have a unique level of detail for representing the display artifact; allowing the user to select from the plurality of paste options; and in response to an indication a user selected a paste option from the plurality of paste options, pasting the display artifact with a level of detail associated with the selected paste option into the input filed.

Abstract: A method of preventing and treating viral infections in animals (and preferably ASFV in porcine), by inhibiting viral ligand interactions with critical cellular receptors that are involved either directly (endo/pinocytosis)) or indirectly (infection through RBCs that have been aggregated by viral interactions) with cellular entry in an animal and preventing and treating the viral infection in the animal. A method of treating a viral infection in an individual with a virus that is both lysogenic and lytic. A composition for treating a viral infection in an individual with a virus that is both lysogenic and lytic. A vaccine for preventing viral infection, including whole and/or partial domains of proteins of both a lysogenic and lytic phase of a virus.

Abstract: Free-space optical (FSO) wireless transmission, including optical communications, remote-sensing, power beaming, etc., can be enhanced by replacing conventional laser sources that operate in the infrared portion of the optical spectrum with ultra-short pulsed laser (USPL) sources having peak pulse powers of one kWatt or greater and pulse lengths of less than one picosecond. Specifically, it has been observed that under these conditions the attenuation of an USPL beam having the same average optical power as a conventional laser in a lossy medium, such as the atmosphere, is substantially less than the attenuation of a conventional laser beam having a lower peak pulse power and/or a longer pulse width. The superior system performance when using an USPL can be translated into an increased distance between a laser source in a transmitter and a photodetector in receiver and/or a higher reliability of system operation in inclement weather conditions.

Abstract: Free-space optical (FSO) wireless transmission, including optical communications, remote-sensing, power beaming, etc., can be enhanced by replacing conventional laser sources that operate in the infrared portion of the optical spectrum with ultra-short pulsed laser (USPL) sources having peak pulse powers of one kWatt or greater and pulse lengths of less than one picosecond. Specifically, it has been observed that under these conditions the attenuation of an USPL beam having the same average optical power as a conventional laser in a lossy medium, such as the atmosphere, is substantially less than the attenuation of a conventional laser beam having a lower peak pulse power and/or a longer pulse width. The superior system performance when using an USPL can be translated into an increased distance between a laser source in a transmitter and a photodetector in receiver and/or a higher reliability of system operation in inclement weather conditions.

Abstract: Disclosed are methods, systems and non-transitory computer readable memory for free-space optical (FSO) communications. For instance, a communications network may include FSO optical transceiver terminals located at remote electrically unpowered locations within the communications network. A remote unpowered FSO terminal located at a far-end location receives necessary optical power from a powered base station location (near-end) required for all optical amplification functions for NRZ or RZ format signals within the spectral range of 900 nm to 1480 nm as well as an Ultra Short Pulsed Laser (USPL) centered at 1560 nm at the far-end location. A transmitting node transmits an optical signal identified as a pump signal to a remote location over a free space medium, such as the atmosphere, where the remote location does not have available electrical power for operation of electro-optic components required for transmission and retransmission functions.

Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicles (Hypo-BioNVs) or Hypo-exosomes including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers. A method of making Hypo-BioNVs. A method of treating an individual with cancer, by administering the Hypo-BioNVs to an individual, targeting cancer cells, and treating the cancer. Hypo-BioNVs including tailored CARs which can recognize target biomarkers through a VERR including viral receptors of an oncolytic virus. A method of treating an individual with cancer, by administering Hypo-BioNVs including CAR receptors to an individual, targeting cancer cells, and treating the cancer. A method of targeting cells in an individual, by administering the Hypo-BioNVs to an individual, and targeting cells to be destroyed or treated for cancer tumors (both liquid and solid), infectious disease, hereditary conditions, autoimmune disease, or metabolic disorders.

Abstract: This invention pertains to the field of free-space optical (FSO) communications, and specifically to the realization of functional FSO optical transceiver terminals located at remote electrically unpowered locations within a communications network. A remote unpowered FSO terminal located at a far-end location receives necessary optical power from a powered base station location (near-end) required for all optical amplification functions necessary for NRZ or RZ format signals within the spectral range of 900 nm to 1480 nm as well as an Ultra Short Pulsed Laser (USPL) centered at 1560 nm at the far-end location. A transmitting node identified as the near-end transmits an optical signal identified as a pump signal to a remote location classified as the far-end node over a free space medium, such as the atmosphere, where the far-end node location does not have available electrical power for operation of electro-optic components required for transmission and retransmission functions.

Abstract: A composition for treating a lysogenic virus, including isolated nucleic acid encoding two or more gene editors chosen from gene editors that target viral DNA, gene editors that target viral RNA, and combinations thereof. A composition for treating a lytic virus, including isolated nucleic acid encoding at least one gene editor that targets viral DNA and a viral RNA targeting composition. A composition for treating both lysogenic and lytic viruses, including isolated nucleic acid encoding two or more gene editors that target viral RNA, chosen from CRISPR-associated nucleases, Argonaute endonuclease gDNAs, C2c2, RNase P RNA, and combinations thereof. A composition for treating lytic viruses, including isolated nucleic acid encoding two or more gene editors that target viral RNA and a viral RNA targeting composition. Methods of treating a lysogenic virus or a lytic virus, by administering the above compositions to an individual having a virus and inactivating the virus.

Abstract: This invention pertains to the field of free-space optical (FSO) communications, and specifically to the realization of functional FSO optical transceiver terminals located at remote electrically unpowered locations within a communications network. A remote unpowered FSO terminal located at a far-end location receives necessary optical power from a powered base station location (near-end) required for all optical amplification functions necessary for NRZ or RZ format signals within the spectral range of 900 nm to 1480 nm as well as an Ultra Short Pulsed Laser (USPL) centered at 1560 nm at the far-end location. A transmitting node identified as the near-end transmits an optical signal identified as a pump signal to a remote location classified as the far-end node over a free space medium, such as the atmosphere, where the far-end node location does not have available electrical power for operation of electro-optic components required for transmission and retransmission functions.

Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.

Abstract: A method of excising undesired DNA or RNA from cells, by administering a composition including a vector encoding at least one gene editor and at least one gRNA to an individual, and excising the DNA or RNA from cells, wherein cut repair is made by microhomology-mediated end joining (MMEJ).

Abstract: A method of preventing and treating viral infections in animals (and preferably ASFV in porcine), by inhibiting viral ligand interactions with critical cellular receptors that are involved either directly (endocytosis and/or macropinocytosis) or indirectly (phagocytosis of RBCs that have been aggregated by viral interactions) with cellular entry in an animal, and preventing and treating the viral infection in the animal. A method of treating a viral infection in an individual with a virus that is both lysogenic and lytic. A composition for treating a viral infection in an individual with a virus that is both lysogenic and lytic. A vaccine for preventing viral infection, including whole and/or partial domains of proteins of both a lysogenic and lytic phase of a virus.

Abstract: Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicles (hypo-bioNVs) including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region or by a viral epitope recognition receptor (VERR). A method of making hypo-bioNVs. A method of treating an individual with cancer, by administering the hypo-bioNVs to an individual, targeting cancer cells, and treating the cancer. A method of targeting cells in an individual, by administering the hypo-bioNVs to an individual, and targeting cells to be destroyed or treated.

Abstract: This invention pertains to the field of free-space optical (FSO) communications, and specifically to the realization of functional FSO optical transceiver terminals located at remote electrically unpowered locations within a communications network. A remote unpowered FSO terminal located at a far-end location receives necessary optical power from a powered base station location (near-end) required for all optical amplification functions necessary for NRZ or RZ format signals within the spectral range of 900 nm to 1480 nm as well as an Ultra Short Pulsed Laser (USPL) centered at 1560 nm at the far-end location. A transmitting node identified as the near-end transmits an optical signal identified as a pump signal to a remote location classified as the far-end node over a free space medium, such as the atmosphere, where the far-end node location does not have available electrical power for operation of electro-optic components required for transmission and retransmission functions.

Abstract: Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicles (Hypo-BioNVs) or Hypo-exosomes including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region, bifunctional or ByTE antibodies, by a viral epitope recognition receptor (VERR), VHH nanobody, Variable New Antigen Receptor (VNAR), engineered TCR, or by any single heavy chain IgG fragment from which a variable region can be engineered. A method of making Hypo-BioNVs. A method of treating an individual with cancer, by administering the Hypo-BioNVs to an individual, targeting cancer cells, and treating the cancer. Hypo-BioNVs including tailored CARs which can recognize target biomarkers through a VERR including viral receptors of an oncolytic virus.

Abstract: Free-space optical (FSO) wireless transmission, including optical communications, remote-sensing, power beaming, etc., can be enhanced by replacing conventional laser sources that operate in the infrared portion of the optical spectrum with ultra-short pulsed laser (USPL) sources having peak pulse powers of one kWatt or greater and pulse lengths of less than one picosecond. Specifically, it has been observed that under these conditions the attenuation of an USPL beam having the same average optical power as a conventional laser in a lossy medium, such as the atmosphere, is substantially less than the attenuation of a conventional laser beam having a lower peak pulse power and/or a longer pulse width. The superior system performance when using an USPL can be translated into an increased distance between a laser source in a transmitter and a photodetector in receiver and/or a higher reliability of system operation in inclement weather conditions.

Abstract: A machine-implemented method of encoding/decoding data is described. The encoding method comprises steps of receiving a message of a given size, the message being represented by a series of units of data, configuring multiple encoding elements (50) in an arrangement having a given frame size, and encoding the message by passing each unit of data through the arrangement so that each unit is processed by at least one of the encoding elements. The frame size of the arrangement is the maximum number of units of data that can pass through the arrangement without any unit of data passing through the arrangement and being processed in the same way as another unit of data.

Abstract: A gripping device comprises: at least two end walls located at opposing ends of the device; at least one elongate channel for receiving an elongate element, the longitudinal axis of the or each channel extending between the two end walls; a gripping element; and biasing means for bringing the gripping element into engagement with an elongate element located in the said channel. The gripping element is mounted for translational movement in a slot. A force component exerted on an elongate element located in the said channel causes the gripping element to move in the slot at towards the elongate element. Each end wall includes at least one hole therethrough, a first hole for receipt of an elongate element into the said channel and a second hole for exit of said elongate element from said channel.